BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38277033)

  • 1. Evaluation of the MTS™ aztreonam-avibactam strip (Liofilchem) on New Delhi metallo-β-lactamase-producing Enterobacterales.
    Emilie CM; Alice CM; Marine G; Farfour E; Pourbaix A; Dortet L; Lucie L; Marc V
    Eur J Clin Microbiol Infect Dis; 2024 Apr; 43(4):777-784. PubMed ID: 38277033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of testing methods assessing the in vitro efficacy of the combination of aztreonam with avibactam on multidrug-resistant Gram-negative bacilli.
    Deckers C; Bélik F; Denis O; Bogaerts P; Montesinos I; Berhin C; Bouchahrouf W; Hoebeke M; Evrard S; Gilliard N; Okur M; Huang TD
    Ann Clin Microbiol Antimicrob; 2024 May; 23(1):47. PubMed ID: 38796461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A practical laboratory method to determine ceftazidime-avibactam-aztreonam synergy in patients with New Delhi metallo-beta-lactamase (NDM)-producing Enterobacterales infection.
    Rawson TM; Brzeska-Trafny I; Maxfield R; Almeida M; Gilchrist M; Gonzalo X; Moore LS; Donaldson H; Davies F
    J Glob Antimicrob Resist; 2022 Jun; 29():558-562. PubMed ID: 35131508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Dilution Susceptibility Testing Methods for Aztreonam in Combination with Avibactam against Enterobacterales.
    Kelley CJ; Kennedy-Mendez A; Walser ON; Thwaites MT; Arhin FF; Pillar CM; Hufnagel DA
    Microbiol Spectr; 2022 Dec; 10(6):e0360122. PubMed ID: 36342288
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Wang W; Huang S; Zou C; Ding Y; Wang H; Pu S; Liao Y; Du H; Wang D; Chen L; Niu S
    Front Cell Infect Microbiol; 2021; 11():755763. PubMed ID: 34778107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?
    Marshall S; Hujer AM; Rojas LJ; Papp-Wallace KM; Humphries RM; Spellberg B; Hujer KM; Marshall EK; Rudin SD; Perez F; Wilson BM; Wasserman RB; Chikowski L; Paterson DL; Vila AJ; van Duin D; Kreiswirth BN; Chambers HF; Fowler VG; Jacobs MR; Pulse ME; Weiss WJ; Bonomo RA
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With Bloodstream Infections Caused by Metallo-β-lactamase-Producing Enterobacterales.
    Falcone M; Daikos GL; Tiseo G; Bassoulis D; Giordano C; Galfo V; Leonildi A; Tagliaferri E; Barnini S; Sani S; Farcomeni A; Ghiadoni L; Menichetti F
    Clin Infect Dis; 2021 Jun; 72(11):1871-1878. PubMed ID: 32427286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aztreonam-Avibactam Susceptibility Testing Program for Metallo-Beta-Lactamase-Producing
    Bhatnagar A; Boyd S; Sabour S; Bodnar J; Nazarian E; Peinovich N; Wagner C; Craft B; Snippes Vagnone P; Simpson J; Stone VN; Therrien M; Bateman A; Lower D; Huang JY; Gumbis S; Lonsway D; Lutgring JD; Karlsson M; Brown AC
    Antimicrob Agents Chemother; 2021 Jul; 65(8):e0048621. PubMed ID: 34060895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of cefiderocol and synergy of novel β-lactam-β-lactamase inhibitor-based combinations against metallo-β-lactamase-producing gram-negative bacilli: insights from a two-year study (2019-2020).
    Boattini M; Comini S; Bianco G; Iannaccone M; Casale R; Cavallo R; Costa C
    J Chemother; 2023 May; 35(3):198-204. PubMed ID: 35731718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of aztreonam in combination with ceftazidime-avibactam against serine- and metallo-β-lactamase-producing Pseudomonas aeruginosa.
    Lee M; Abbey T; Biagi M; Wenzler E
    Diagn Microbiol Infect Dis; 2021 Jan; 99(1):115227. PubMed ID: 33086177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Susceptibility Testing Methods for Aztreonam and Ceftazidime-Avibactam Combination Therapy on Extensively Drug-Resistant Gram-Negative Organisms.
    Khan A; Erickson SG; Pettaway C; Arias CA; Miller WR; Bhatti MM
    Antimicrob Agents Chemother; 2021 Oct; 65(11):e0084621. PubMed ID: 34424044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of a simple method for testing aztreonam and ceftazidime-avibactam synergy in New Delhi metallo-beta-lactamase producing Enterobacterales.
    Khan S; Das A; Vashisth D; Mishra A; Vidyarthi AJ; Gupta R; Begam NN; Kataria B; Bhatnagar S
    PLoS One; 2024; 19(5):e0303753. PubMed ID: 38758757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Avibactam potentiated the activity of both ceftazidime and aztreonam against S. maltophilia clinical isolates in vitro.
    Lin Q; Zou H; Chen X; Wu M; Ma D; Yu H; Niu S; Huang S
    BMC Microbiol; 2021 Feb; 21(1):60. PubMed ID: 33618662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the in vitro impact of ceftazidime on aztreonam/avibactam susceptibility testing for highly resistant MBL-producing Enterobacterales.
    Bhatnagar A; Ransom EM; Machado MJ; Boyd S; Reese N; Anderson K; Lonsway D; Elkins CA; Rasheed JK; Patel JB; Karlsson M; Brown AC; Lutgring JD
    J Antimicrob Chemother; 2021 Mar; 76(4):979-983. PubMed ID: 33367916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid Aztreonam/Avibactam NP test for detection of aztreonam/avibactam susceptibility/resistance in Enterobacterales.
    Viguier C; Bouvier M; Sadek M; Kerbol A; Poirel L; Nordmann P
    J Clin Microbiol; 2023 Oct; 61(10):e0058823. PubMed ID: 37791761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of aztreonam-avibactam and comparators against Metallo-β-Lactamase-producing Enterobacterales from ATLAS Global Surveillance Program, 2016-2020.
    Rossolini GM; Arhin FF; Kantecki M
    J Glob Antimicrob Resist; 2024 Mar; 36():123-131. PubMed ID: 38154750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Occurrence of multi-carbapenemases producers among carbapenemase-producing Enterobacterales and in vitro activity of combinations including cefiderocol, ceftazidime-avibactam, meropenem-vaborbactam, and aztreonam in the COVID-19 era.
    Bianco G; Boattini M; Comini S; Casale R; Iannaccone M; Cavallo R; Costa C
    Eur J Clin Microbiol Infect Dis; 2022 Apr; 41(4):573-580. PubMed ID: 35061145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of aztreonam/avibactam against metallo-β-lactamase-producing Enterobacterales from the UK: Impact of penicillin-binding protein-3 inserts and CMY-42 β-lactamase in Escherichia coli.
    Livermore DM; Mushtaq S; Vickers A; Woodford N
    Int J Antimicrob Agents; 2023 May; 61(5):106776. PubMed ID: 36893810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Susceptibility testing for aztreonam plus ceftazidime/avibactam combination: A general guidance for clinical microbiology laboratories in India.
    Bakthavatchalam YD; Walia K; Veeraraghavan B
    Indian J Med Microbiol; 2022; 40(1):3-6. PubMed ID: 34949482
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Huang YS; Chen PY; Chou PC; Wang JT
    Microbiol Spectr; 2023 Jun; 11(3):e0056923. PubMed ID: 37154758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.